Free Trial

GoodRx (GDRX) Stock Price, News & Analysis

-0.35 (-4.68%)
(As of 05/20/2024 ET)
Today's Range
50-Day Range
52-Week Range
1.71 million shs
Average Volume
1.56 million shs
Market Capitalization
$2.68 billion
P/E Ratio
Dividend Yield
Price Target

GoodRx MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.50 Rating Score
26.2% Upside
$9.00 Price Target
Short Interest
Dividend Strength
News Sentiment
0.21mentions of GoodRx in the last 14 days
Based on 27 Articles This Week
Insider Trading
Proj. Earnings Growth
From $0.23 to $0.31 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.67 out of 5 stars

Medical Sector

405th out of 918 stocks

Data Processing & Preparation Industry

25th out of 57 stocks

GDRX stock logo

About GoodRx Stock (NASDAQ:GDRX)

GoodRx Holdings, Inc., together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices. It also offers other healthcare products and services, including subscriptions, and pharma manufacturer solutions, as well as telehealth services through the GoodRx Care platform. It serves pharmacy benefit managers who manage formularies and prescription transactions, including establishing pricing between consumers and pharmacies. The company was founded in 2011 and is headquartered in Santa Monica, California.

GDRX Stock Price History

GDRX Stock News Headlines

Wegovy vs. Zepbound: Who Wins the Battle of the GLP-1 Drugs?
The GLP-1 weight loss trend continues to flourish, and the ante keeps rising. The reigning champions in the battle of the bulge are Novo Nordisk A/V NYSE: NVO with its Semaglutide medications Ozempic and Wegovy, and Eli Lilly & Co. NYSE: LLY with its Tirzepatide medications Mounjaro and Zepbound.
Wegovy vs. Zepbound: Who Wins the Battle of the GLP-1 Drugs? (GDRX)
The GLP-1 weight loss trend continues to flourish, and the ante keeps rising; see how the winner between Wegovy and Zepbound can help your portfolio
GoodRx (NASDAQ:GDRX) Stock Price Down 4.5%
GoodRx (NASDAQ:GDRX) PT Raised to $16.00 at TD Cowen
Raymond James Upgrades GoodRx (NASDAQ:GDRX) to "Outperform"
GoodRx (NASDAQ:GDRX) Shares Gap Up Following Analyst Upgrade
KeyBanc Remains a Buy on GoodRx Holdings (GDRX)
See More Headlines
Receive GDRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for GoodRx and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Industry, Sector and Symbol

Data processing & preparation
Current Symbol
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Moderate Buy
Rating Score (0-4)
Research Coverage
20 Analysts


Net Income
Pretax Margin


Sales & Book Value

Annual Sales
$750.27 million
Cash Flow
$0.39 per share
Book Value
$1.93 per share


Free Float
Market Cap
$2.68 billion
The 10 Best AI Stocks to Own in 2024 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

GDRX Stock Analysis - Frequently Asked Questions

Should I buy or sell GoodRx stock right now?

20 Wall Street analysts have issued "buy," "hold," and "sell" ratings for GoodRx in the last year. There are currently 1 sell rating, 8 hold ratings and 11 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" GDRX shares.
View GDRX analyst ratings
or view top-rated stocks.

What is GoodRx's stock price target for 2024?

20 equities research analysts have issued 12-month target prices for GoodRx's stock. Their GDRX share price targets range from $4.50 to $16.00. On average, they expect the company's share price to reach $9.00 in the next year. This suggests a possible upside of 26.2% from the stock's current price.
View analysts price targets for GDRX
or view top-rated stocks among Wall Street analysts.

How have GDRX shares performed in 2024?

GoodRx's stock was trading at $6.70 on January 1st, 2024. Since then, GDRX shares have increased by 6.4% and is now trading at $7.13.
View the best growth stocks for 2024 here

When is GoodRx's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 14th 2024.
View our GDRX earnings forecast

How were GoodRx's earnings last quarter?

GoodRx Holdings, Inc. (NASDAQ:GDRX) announced its quarterly earnings data on Thursday, February, 29th. The company reported $0.02 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.02. The firm had revenue of $196.64 million for the quarter, compared to analyst estimates of $195.59 million. GoodRx had a negative net margin of 0.86% and a positive trailing twelve-month return on equity of 3.45%.

What ETFs hold GoodRx's stock?
What guidance has GoodRx issued on next quarter's earnings?

GoodRx issued an update on its FY 2024 earnings guidance on Thursday, May, 9th. The company provided EPS guidance of for the period. The company issued revenue guidance of $800.0 million-$810.0 million, compared to the consensus revenue estimate of $801.0 million.

What other stocks do shareholders of GoodRx own?

Based on aggregate information from My MarketBeat watchlists, some companies that other GoodRx investors own include Gilead Sciences (GILD), NVIDIA (NVDA), AbbVie (ABBV), Bristol-Myers Squibb (BMY), DraftKings (DKNG), GW Pharmaceuticals (GWPH), Rocket Companies (RKT), AT&T (T), Advanced Micro Devices (AMD) and Alteryx (AYX).

When did GoodRx IPO?

GoodRx (GDRX) raised $900 million in an IPO on Wednesday, September 23rd 2020. The company issued 34,600,000 shares at $24.00-$28.00 per share. Morgan Stanley, Goldman Sachs, J.P. Morgan and Barclays acted as the underwriters for the IPO and BofA Securities, Citigroup, Credit Suisse, RBC Capital Markets, UBS Investment Bank, Cowen, Deutsche Bank Securities, Evercore ISI, Citizens Capital Markets, KKR, LionTree, Raymond James, SVB Leerink, Academy Securities, Loop Capital Markets, R. Seelaus and Ramirez were co-managers.

Who are GoodRx's major shareholders?

GoodRx's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (2.05%), Assenagon Asset Management S.A. (0.26%), Picton Mahoney Asset Management (0.12%), GSA Capital Partners LLP (0.06%), Susquehanna Portfolio Strategies LLC (0.05%) and Mirae Asset Global Investments Co. Ltd. (0.05%). Insiders that own company stock include Abdiel Capital Management, Llc, Agnes Rey-Giraud, Andrew Slutsky, Babak Azad, Bansi Nagji, Douglas Joseph Hirsch, Idea Men, Llc, Karsten Voermann, Lake Group LLC Silver, Scott Wagner and Trevor Bezdek.
View institutional ownership trends

How do I buy shares of GoodRx?

Shares of GDRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:GDRX) was last updated on 5/21/2024 by Staff

From Our Partners